India’s Cumulative COVID-19 Vaccination Coverage crossed landmark milestone of 42 Cr

New Delhi: India’s COVID-19 vaccination coverage crossed 42crores landmark yesterday. Cumulatively,42,34,17,030 vaccine doses have been administered through 51,94,364sessions, as per the provisional report till 7 am today. 54,76,423 vaccine doses were administered in the last 24 hours.

These include:

 

HCWs 1st Dose 1,02,80,416
2nd Dose 76,51,103
FLWs 1st Dose 1,78,34,482
2nd Dose 1,06,40,254
Age Group 18-44 years 1st Dose 13,33,04,056
2nd Dose 55,55,468
Age Group 45-59 years 1st Dose 9,95,79,752
2nd Dose 3,25,92,396
Over 60 years 1st Dose 7,29,46,445
2nd Dose 3,30,32,658
Total 42,34,17,030

 

The new phase of universalization of COVID-19 vaccination has commenced from 21st June, 2021. The Union Government is committed to accelerating the pace and expanding the scope of COVID-19 vaccination throughout the country.

Out of the people infected since the beginning of the pandemic, 3,04,68,079 people have already recovered from COVID-19 and 38,740 patients have recovered in the last 24 hours. This constitutes an overall recovery rate of 97.36%.

 

India has reported 35,342 daily new cases in the last 24 hours.

Less than 50,000 Daily New Cases have been reported since twenty-six continuous days. This is a result of sustained and collaborative efforts by the Centre and the States/UTs.

India’s Active Caseload today stands at 4,05,513 and active cases now constitute 1.30% of the country’s total Positive Cases.

With substantially ramped up testing capacity across the country, a total of 16,68,561 tests were conducted in the last 24 hours in the country. Cumulatively, India has conducted over 45.29 crore (45,29,39,545) tests so far.

While on one side testing capacity has been enhanced across the country, Weekly Positivity Rate is currently at 2.14% and the Daily Positivity rate stands at 2.12% today. Daily Positivity rate has remained less than 3% for 32 consecutive days, and has remained below 5%for 46 consecutive days now.

 

****

Comments are closed.